Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention)
| Autor: | Yangsoo Jang, Hyo-Soo Kim, In Ho Chae, Seung Ho Hur, Seung Hwan Lee, Hun S. Park, Seung-Woon Rha, Min-Ho Lee, Si Hyuck Kang, Cheol Woong Yu, Moo H. Kim, Hyeon Cheol Gwon, Joo Myung Lee, Chang Hwan Yoon |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Paclitaxel medicine.medical_treatment Population Antineoplastic Agents Coronary Angiography Electrocardiography Percutaneous Coronary Intervention Internal medicine Republic of Korea medicine Humans Everolimus Registries cardiovascular diseases Myocardial infarction education Retrospective Studies Sirolimus education.field_of_study business.industry Percutaneous coronary intervention Stent Drug-Eluting Stents Retrospective cohort study Middle Aged medicine.disease Survival Rate Treatment Outcome Coronary Occlusion Chronic Disease Cohort Cardiology Female Cardiology and Cardiovascular Medicine business Immunosuppressive Agents Mace Follow-Up Studies medicine.drug |
| Zdroj: | The American Journal of Cardiology. 116:195-203 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2015.04.010 |
| Popis: | For the treatment of chronic total occlusion (CTO), the efficacy and safety of the everolimus-eluting stent (EES) remain less well defined. Also, there are limited data for the predictors of outcome after CTO intervention. The purpose of this study was to compare clinical outcomes of the EES with the first-generation drug-eluting stent (DES) in CTO intervention and to investigate the predictors of clinical outcome. The Korean National Registry of CTO Intervention is a retrospective cohort of 26 centers from the past 5 years. The primary end point was major adverse cardiovascular events (MACE) defined as a composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization. Of the 1,754 all-comer patients, 1,509 patients (EES 311, sirolimus-eluting stent [SES] 642, paclitaxel-eluting stent 556) were finally analyzed after excluding 245 patients (mixed DESs in 46 and follow-up loss in 199). In the inverse probability weighting-adjusted population, the 1-year MACE rate of the EES was comparable with that of the SES (5.8% vs 3.4%, p = 0.796) and the paclitaxel-eluting stent (5.8% vs 6.9%, p = 0.740). Each component of MACE was also comparable among the 3 stents. Importantly, the independent predictors of MACE were diabetes mellitus, previous congestive heart failure, and left circumflex CTO. In conclusion, for the first time in the largest CTO cohort, the EES showed good 1-year clinical outcomes that were comparable with the SES. Independent predictors of MACE after CTO intervention were clinical factors (diabetes and congestive heart failure) and lesion location. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect